ACE-2 BLOCKER
DEAD

Serial Number

90316319

Owner

Sotira, LLC

Attorney

Rick Chang

Filing Date

Nov 12, 2020

Add to watchlist:

No watchlists yet
View on USPTO

ACE-2 BLOCKER Trademark

Serial Number: 90316319

ACE-2 BLOCKER is a trademark filed by Sotira, LLC on November 12, 2020. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

Sotira, LLC (5 trademarks)

2525 E Camelback Rd Ste 800
Phoenix, AZ 85016

Entity Type: 16

Trademark Details

Filing Date

November 12, 2020

Registration Date

Not Registered

Goods & Services

Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Pharmaceutical preparations for the prevention of SARS-CoV2; Pharmaceutical preparations for the prevention of hypertension, inflammation, fibrosis, cardiovascular, and kidney diseases; Pharmaceutical preparations for the treatment and prevention of SARS-CoV2; Pharmaceutical preparations for the treatment and prevention of hypertension, inflammation, fibrosis, cardiovascular, and kidney diseases; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the treatment of kidney diseases; Pharmaceutical preparations for the treatment of viral diseases; Pharmaceutical preparations for the treatment of viral infections; Pharmaceutical preparations for the treatment of SARS-CoV2; Pharmaceutical preparations for the treatment of hypertension, inflammation, fibrosis, cardiovascular, and kidney diseases; Pharmaceutical preparations for modulating ACE-2 receptors; Pharmaceutical products for treating respiratory diseases; Inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; Inhalers filled with ACE-2 inhibitors; Therapeutic pharmaceutical for the treatment of SARS-CoV2; Therapeutic pharmaceutical for the treatment of hypertension, inflammation, fibrosis, cardiovascular, and kidney diseases

Filing History

ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Nov 16, 2021 MAB2
ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Nov 16, 2021 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Nov 16, 2021 ABN2
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 4, 2021 GNRN
NON-FINAL ACTION E-MAILED
May 4, 2021 GNRT
NON-FINAL ACTION WRITTEN
May 4, 2021 CNRT
ASSIGNED TO EXAMINER
Apr 29, 2021 DOCK
ASSIGNED TO EXAMINER
Apr 28, 2021 DOCK
ASSIGNED TO EXAMINER
Apr 21, 2021 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 12, 2021 NWOS
NEW APPLICATION ENTERED
Nov 16, 2020 NWAP